Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)

Conditions

• Hypercholesterolaemia

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Alirocumab — DRUG
  Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
• Placebo (for alirocumab) — DRUG
  Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
• Lipid Modifying Therapy (LMT) — DRUG
  Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.

Study Details

Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9). Primary Objective of the study: To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 24 weeks of treatment in comparison with placebo. Secondary Objectives: * To evaluate the effect of alirocumab in comparison with placebo on LDL-C at other time points * To evaluate the effects of alirocumab on other lipid parameters * To evaluate the safety and tolerability of alirocumab

Key Dates

Start date

Jun 30, 2012

Status verified

Sep 2016

Primary completion

May 31, 2014

Completion

Jan 31, 2015

Study Design

Enrollment

107 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Placebo Comparator: Placebo Q2W
  Placebo for alirocumab subcutaneous (SC) injection every two weeks (Q2W) on top of stable lipid-modifying therapy (LMT) for 78 weeks.
• Experimental: Alirocumab 150 mg Q2W
  Alirocumab 150 mg SC injection Q2W on top of stable LMT for 78 weeks.

Primary Outcome Measure

Percent Change From Baseline in Calculated LDL-C at Week 24 - ITT Analysis [ Time Frame: From Baseline to Week 52 ]

Locations (14)

Find similar trials in Bell Gardens, CA

Related Studies

• A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
  PHASE1 · Recruiting · CRISPR Therapeutics AG · Jacksonville, Florida